Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Teva announced the launch of Oral Transmucosal Fentanyl Citrate (OTFC) Lozenges, the generic version of Cephalon‘s Actiq.
RELATED: Opioid Equianalgesic Doses
Actiq is indicated for breakthrough cancer pain in patients aged ≥16 years who are receiving and are tolerant to opioids (opioid tolerance is defined as taking at least 60mg of morphine/day, transdermal fentanyl 25mcg/hr, at least 30mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, at least 25mg oral oxymorphone daily, or an equianalgesic dose of another opioid daily for a week or longer). It is a pure opioid agonist whose principal therapeutic action is analgesia.
Oral Transmucosal Fentanyl Citrate Lozenges are available as 200mcg, 400mcg, 600mcg, 800mcg, 1200mcg, and 1600mcg strengths in 1×30 blister packs.
For more information call (888) 838-2872 or visit TevaGenerics.com.
